Open-label PrEP in Botswana: very high adherence and no HIV infections seen

Faith Henderson at IAS 2015 photo ©Marcus Rose/IAS
Gus Cairns
Published: 05 August 2015

A study of open-label Truvada HIV pre-exposure prophylaxis (PrEP) in Botswana among heterosexual people found very high adherence rates. Around 90% of participants had useful levels of the drug in their blood; there was a high concordance between self-reported adherence and drug levels; and there were no HIV infections, the Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) was told last month.

The participants had all previously taken part in the TDF2 placebo-controlled study of PrEP which took place between 2007 and 2011 and found an efficacy of 62% for PrEP versus placebo.

For the present study, attempts were made to contact all the 1219 participants in the original TDF2 study. Presenter Faith Henderson of the US Centers for Disease Control and Prevention (CDC) commented that, with a three-year gap and a highly mobile population in Botswana, it was hard to contact all participants. However, 736 TDF2 participants (60%) were eventually traced. Of these, 229 (31%) were eligible to take PrEP using the same criteria as the original TDF2 study – which, in this very high-prevalence country, were that they were between 19 and 39 years old (90% in TDF2 were in fact in their 20s) and were sexually active. The main reasons for exclusion were that the person was now HIV positive, had blood results indicative of kidney disease or, for women, that they were pregnant or breastfeeding.

Truvada and condoms were dispensed once a month and participants were tested for HIV and received risk-reduction counselling once every three months. Participants also received text messages or phone calls as adherence reminders.

Of the 229 people enrolled, 60% completed ten or more of the maximum of twelve monthly study visits and the number of patient-years of data collected was 76% of the possible maximum. Fifty-six per cent of participants were male, and women were about 60% more likely not to complete the study – the reasons why are being investigated in qualitative studies. The only other factor associated with non-completion was that people who experienced significant side-effects were twice as likely not to complete the study.

The open-label study was primarily designed to measure any behavioural change and also to measure adherence. Averaged over each monthly visit, 71% of participants reported only one sexual partner in the previous month, 9% two and 2.4% three or more (not all participants reported number of partners). The average number of sexual partners in the previous month stayed at about one for men during the study, but declined from one to about 0.75 in women. The average number of self-reported condomless sex acts in the previous month declined from 1.9 to 1.2 in men and from 1.45 to 0.95 in women.

Self-reported adherence was high. When asked if they had taken Truvada in the last three days before their clinic visit, 88% said they had taken it all three times, 5.5% once or twice and 6.7% had taken none.

Altogether, 120 completing participants (52%) had drug levels measured in blood samples for tenofovir. Among these, 100% had tenofovir levels over five nanograms per millilitre (ng/ml), indicative of some use in the last week, and 94% over 25ng/ml, indicating clinically useful levels. These levels were concordant with self-reported adherence: in samples from participants who said they had taken all three pills in the last three days, drug levels were over 25ng/ml in 92% of women and 98% of men; if two doses were reported, drug levels were over 25ng/ml in 90%; if once in the last three days, 86.5%; and if no doses were reported in the last three days, 42% of women and 73% of men had levels over 25ng/ml.

In a subset of 30 participants, the proportion of people with levels over 25ng/ml were 93%, 93%, 100%, 93% and 90% at months one, three, six, nine and twelve of the study, so there was no or little evidence of any falling-off in adherence. Women were 9% less likely than men to have clinically useful tenofovir blood levels and people who did not report any condomless sex also had slightly lower adherence, though this difference was not significant.

No HIV infections occurred in any study participant. Although this was not designed as an efficacy study, five or six HIV infections would have occurred if background HIV incidence was at the rate seen in the placebo arm of the original TDF2 study (3.1% a year).

Further drug level analysis and qualitative data will be presented, but – although there must be a big caveat about the use of text and phone reminders in this study – it does show that high and effective adherence levels to PrEP can be reached among an African heterosexual population who are in need of it.

The big question now is whether the Botswana government and other agencies will extend their already impressive level of antiretroviral therapy provision to people with HIV to cover PrEP provision for the proportion of HIV-negative people who remain at significant risk.

Reference

Henderson F et al. Characteristics and oral PrEP adherence in the TDF2 open-label extension in Botswana. Eighth IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), Vancouver. Abstract TUAC0203, 2015.

You can download the slides of this presentation from the conference website.

A webcast of this presentation is available on the conference YouTube channel.

Where available, you can view details of sessions, view abstracts, download presentation slides and find webcasts using the conference 'Programme at a Glance' tool.

You can also download a PDF of the abstract book from the conference website.

E-atlas

Botswana

Find details of HIV services in Botswana, the latest news from the country, and a selection of resources from local organisations.

Find out more about Botswana >

NAM's coverage of the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) has been made possible thanks to support from Bristol-Myers Squibb, Gilead, Merck & Co., Inc., and ViiV Healthcare.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.